Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs were updated May 1, 2024:
Effective June 1, 2024:
- Cibinqo
- IL-13 Antagonist
- IL-4 Inhibitor
- IL-5 Inhibitors
- Zoryve
- IL-1 Inhibitor
- Lupus
- Xolair
- Soliris/Ultomiris
- Empaveli (
- Agamree, Emflaza (formerly Emflaza)
- Fabhalta
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.